Bright future or blind alley? CAR-T cell therapy for solid tumors

Bright future or blind alley? CAR-T cell therapy for solid tumors

Blog Article

Chimeric antigen receptor (CAR) T cells Surge Protection Devices therapy has emerged as a significant breakthrough in adoptive immunotherapy for hematological malignancies with FDA approval.However, the application of CAR-T cell therapy in solid tumors remains challenging, mostly due to lack of suitable CAR-T target antigens, insufficient trafficking and extravasation to tumor sites, and limited CAR-T survival in the hostile tumor microenvironment (TME).Herein, we reviewed the development of CARs and the clinical trials in solid tumors.

Meanwhile, a “key-and-lock” relationship was used to describe the recognition of tumor antigen via CAR T cells.Some strategies, including dual-targets and receptor system switches or filter, have been explored to help CAR T cells matching targets specifically and to minimize on-target/off-tumor toxicities in normal tissues.Furthermore, the complex TME restricts CAT T cells activity through dense extracellular matrix, suppressive immune cells and cytokines.

Recent Surcingle Stoppers innovations in engineered CARs to shield the inhibitory signaling molecules were also discussed, which efficiently promote CAR T functions in terms of expansion and survival to overcome the hurdles in the TME of solid tumors.